Predictors for success of renal denervation in patients with resistant arterial hypertension

Objective. Development of principles for personalized selection of patients for renal denervation (RD) based on the evaluation of procedural response predictors. Design and methods. In the period from 2016 to 2022, 91 patients with resistant arterial hypertension (RHTN) underwent a RD procedure using 2 types of catheters — monopolar and spiral. All patients were assessed for basic demographic, clinical, functional, and laboratory characteristics. The reassessment was carried out on the 7th day, then after 6 and 12 months. A predictive model for determining the probability of response to RD was constructed using the logistic regression method. Results. The final analysis included data from 91 RHTN patients, the mean age was 57,79 ± 9,5 years. At baseline, patients received 4,5 ± 1,4 antihypertensive drugs. Initial office systolic blood pressure (SBP) was 190 (interquartile range (IQR) 100; 140, 240) mm Hg, diastolic blood pressure (DBP) — 100 (IQR 60; 80, 140) mm Hg. Among the responders, a significant reduction in blood pressure (BP) was achieved, with maintenance of the antihypertensive effect during 1 year of follow-up (p < 0,001 for SBP and DBP). The multivariate regression analysis showed that the initial DPB (p < 0,001), the diameter of the right (p = 0,049) and left renal arteries (RA) (p = 0,038) were significant predictors. Based on these data, a prognostic model was developed (p < 0,001). Conclusions. Our results confirmed effectiveness and safety of RD. The stability of the clinical effect is important. However, there was a high variability in the degree of BP reduction after the procedure. The initial DBP, the diameter of the left and right RA, and the use of drugs that reduce the activity of the sympathetic nervous system can be used as possible predictors of response to RD.

1. Abbafati C, GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019:a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-1249. doi:10.1016/S01406736(20)30752-2

2. Balanova YuA, Shalnova SA, Imaeva AE, Kapustina АУ, Muromtseva GA, Evstifeeva SV et al. Prevalence, awareness, treatment and control of hypertension in Russian Federation (data of observational ESSE-RF-2 Study). Rat Pharmacother Cardiol. 2019;15(4):450-466. doi:10.20996/1819-6446-2019-15-4-450-466. In Russian.

3. Supiyev A, Kossumov A, Utepova L, Nurgozhin T, Zhumadilov Z, Bobak M. Prevalence, awareness, treatment and control of arterial hypertension in Astana, Kazakhstan. A crosssectional study. Public Health. 2015;129(7):948-953. doi:10.1016/j.puhe.2015.02.020

4. SPRINT Research Group, Jackson TW, Jeff DW, Paul KW, Snyder JK, Sink KM, Rocco MV et al. A randomized trial of intensive versus standard blood-pressure control. The SPRINT Research Group. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939

5. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sunet G al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385(14):1268-1279. doi:10.1056/NEJMoa2111437

6. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al. 2018 practice guidelines for the management of arterial hypertension of the European society of cardiology and the European society of hypertension ESC/ESH task force for the management of arterial hypertension. J Hypertens. 2018;36(12):2284-2309. doi:10.1097/HJH.0000000000001961

7. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison Himmelfarb CR et al. Resistant hypertension: detection, evaluation, and management a scientific statement from the American Heart Association. Hypertension. 2018;72(5):53-90. doi:10.1161/HYP.0000000000000084

8. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-1401. doi:10.1056/NEJMoa1402670

9. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-1451. doi:10.1016/S01406736(20)30554-7

10. Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346-2355. doi:10.1016/S0140-6736(18)30951-6

11. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022;400(10361):1405-1416. doi:10.1016/S0140-6736(22)01787-1

12. Mahfoud F, Azizi M, Ewen S, Pathak A, Ukena C, Blankestijn PJ et al. Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. Eur Heart J. 2020;41(16):1588-1599. doi:10.1093/eurheartj/ehaa121

13. Reshetnik A, Gohlisch C, Scheurig-Münkler C, Bucourt MD, Zidek W, Tolle M et al. Predictors for success in renal denervation — a single centre retrospective analysis. Sci Rep Nature Publishing Group. 2018;8(1):15505. doi:10.1038/s41598-018-33783-3

14. Esler M, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-1909. doi:10.1016/S0140-6736(10)62039-9

15. Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR et al. Renal denervation for treating hypertension: current scientific and clinical evidence. JACC Cardiovasc Interv. 2019;12(12):1095-1105. doi:10.1016/j.jcin.2019.02.050

16. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH et al. KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3): S 1-S 87. doi:10.1016/j.kint.2020.11.003

17. Orekhov AU, Sabitov YT, Karazhanova LK. Renal denervation in resistant hypertension treatment. Bratisl Lek Listy. 2022;123(10):710-715. doi:10.4149/BLL_2022_113

18. Schmieder RE, Mahfoud F, Mancia G, Azizi M, Bohm M, Dimitriadis K et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733-1741. doi:10.1097/HJH.0000000000002933

19. Aksenova AV, Sivakova OA, Blinova NV, Danilov NM, Elfimova EM, Kisliak OA et al. Russian Medical Society for Arterial Hypertension expert consensus. Resistant hypertension: detection and management. Terapevticheskii Arkhiv = Ter Arkh. 2021;93(9):1018-1029. doi:10.26442/00403660.2021.09.201007. In Russian.

20. Mahfoud F, Bohm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40(42):3474-3482. doi:10.1093/eurheartj/ehz118

21. Ionov MV, Emelyanov IV, Vakhrushev AD, Alieva AS, Avdonina NG, Yudina YuS et al. Experience of using multielectrode catheter systems to perform radiofrequency renal sympathetic denervation in patients with resistant hypertension: immediate procedural effects. Russ J Cardiol. 2022;27(2):4794. doi:10.15829/1560-4071-2022-4794. In Russian.

22. Böhm M, Mahfoud F, Townsend RR, Kandzari DE, Pocock S, Ukena C et al. Ambulatory heart rate reduction after catheterbased renal denervation in hypertensive patients not receiving antihypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. Eur Heart J. 2019;40(9):743-751. doi:10.1093/eurheartj/ehy871

23. Zhou H, Xu Y, Chen W, Wang L, Du H, Liu H et al. Present evidence of determinants to predict the efficacy of renal denervation. Int J Hypertens. 2022;2022:5694127. doi:10.1155/2022/5694127

24. Hoogerwaard AF, Jong MR, Adiyaman A, Smit JJ, Delnoy PP, Heeg JE et al. Renal sympathetic denervation induces changes in heart rate variability and is associated with a lower sympathetic tone. Clin Res Cardiol Springer Berlin Heidelberg. 2019;108(1):22-30. doi:10.1007/s00392-018-1307-2

25. Li S, Phillips JK. Patient selection for renal denervation in hypertensive patients: what makes a good candidate? Vasc Health Risk Manag. 2022;18:375-386. doi:10.2147/VHRM.S270182

26. Lauder L, Ewen S, Tzafriri AR, Edelman ER, Luscher TF, Blankenstijn PJ et al. Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1000 patients with hypertension Lucas. EuroIntervention. 2019;14(1):121-128. doi:10.4244/EIJ-D-18-00112

27. Wolf M, Hubbard B, Sakaoka A, Rousselle S, Tellez A, Jiang X et al. Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model. J Hypertens. 2018;36(12):2453-2459. doi:10.1097/HJH.0000000000001840

28. Garda-Touchard A, Maranillo E, Mompeo B, Sañudo JR. Microdissection of the human renal nervous system: implications for performing renal denervation procedures. Hypertension. 2020;76(4):1240-1246. doi:10.1161/HYPERTENSIONAHA.120.15106

29. Vakhrushev AD, Emelyanov IV, Lebedev DS, Alieva AS, Mikhaylov EN. Radiofrequency renal artery denervation: technical issues of different approaches and safety. Arterial'naya Gipertenziya = Arterial Hypertension. 2020;26(5):543-551. doi:10.18705/1607-419X-2020-26-5-543-55. In Russian.

30. Kim BK, Kim HS, Park SJ, Park CG, Seung KB, Gwon HC et al. Long-term outcomes after renal denervation in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). Hypertens Res. 2021;44(9):1099-1104. doi:10.1038/s41440-021-00683-5

31. Kario K, Kim BK, Aoki J, Wong A, Lee YH, Wongprapa-rut N et al. Renal denervation in Asia: consensus statement of the Asia renal denervation consortium. Hypertension. 2020;75(3):590-602. doi:10.1161/HYPERTENSIONAHA.119.13671